Effect of nucleoside reverse transcriptase inhibitors on innate immune priming

2023-510378-14-00 Protocol PHARM-202202 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 20 Jun 2024 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol PHARM-202202

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 12
Countries 1
Sites 1

modulation of the innate immune system in healthy subjects

Key facts

Sponsor
Rheinische Friedrich-Wilhelms-Universitaet Bonn
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Phenomena and Processes [G] - Microbiological Phenomena [G06], Diseases [C] - Virus Diseases [C02], Phenomena and Processes [G] - Immune system processes [G12], Phenomena and Processes [G] - Immune System Phenomena [G13]
Trial duration
20 Jun 2024 → ongoing
Decision date (initial)
2024-05-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

modulation of the innate immune system in healthy subjects

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Rheinische Friedrich-Wilhelms-Universitaet Bonn

Sponsor organisation
Rheinische Friedrich-Wilhelms-Universitaet Bonn
Address
Venusberg-Campus 1, Venusberg Venusberg
City
Bonn
Postcode
53127
Country
Germany

Scientific contact point

Organisation
Rheinische Friedrich-Wilhelms-Universitaet Bonn
Contact name
Prof. Dr. rer. nat. Rayk Behrendt

Public contact point

Organisation
Rheinische Friedrich-Wilhelms-Universitaet Bonn
Contact name
Prof. Dr. rer. nat. Rayk Behrendt

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruitment ended 12 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruitment ended
Rheinische Friedrich-Wilhelms-Universitaet Bonn
Phase I-Unit, Institute of Clinical Chemistry and Clinical Pharmacology, Venusberg-Campus 1, Venusberg, Bonn

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-06-20 2024-06-21 2024-10-21

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-15 Germany Acceptable
2024-04-22
2024-05-08
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-16